These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9144102)

  • 1. Methylphenidate treatment of negative symptoms in patients with dementia.
    Galynker I; Ieronimo C; Miner C; Rosenblum J; Vilkas N; Rosenthal R
    J Neuropsychiatry Clin Neurosci; 1997; 9(2):231-9. PubMed ID: 9144102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of psychiatric symptoms in vascular dementia and Alzheimer's disease.
    Sultzer DL; Levin HS; Mahler ME; High WM; Cummings JL
    Am J Psychiatry; 1993 Dec; 150(12):1806-12. PubMed ID: 8238634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Depression and frontal dysfunction: risks for the elderly?].
    Thomas P; Hazif Thomas C; Billon R; Peix R; Faugeron P; Clément JP
    Encephale; 2009 Sep; 35(4):361-9. PubMed ID: 19748373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychological and biomedical assessment of depression-dementia syndromes.
    Stoudemire A; Hill C; Gulley LR; Morris R
    J Neuropsychiatry Clin Neurosci; 1989; 1(4):347-61. PubMed ID: 2521082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms.
    Amieva H; Le Goff M; Millet X; Orgogozo JM; Pérès K; Barberger-Gateau P; Jacqmin-Gadda H; Dartigues JF
    Ann Neurol; 2008 Nov; 64(5):492-8. PubMed ID: 19067364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anosognosia in Alzheimer's disease: association with patient characteristics, psychiatric symptoms and cognitive deficits.
    Kashiwa Y; Kitabayashi Y; Narumoto J; Nakamura K; Ueda H; Fukui K
    Psychiatry Clin Neurosci; 2005 Dec; 59(6):697-704. PubMed ID: 16401246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease and depression: neuropsychological impairment and progression of the illness.
    Lopez OL; Boller F; Becker JT; Miller M; Reynolds CF
    Am J Psychiatry; 1990 Jul; 147(7):855-60. PubMed ID: 2356870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexistence of cognitive impairment and depression in geriatric outpatients.
    Reifler BV; Larson E; Hanley R
    Am J Psychiatry; 1982 May; 139(5):623-6. PubMed ID: 7072849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methylphenidate augmentation of fluvoxamine for treatment-resistant depression: a case report and review literature].
    Buhagiar K; Cassar J
    Turk Psikiyatri Derg; 2007; 18(2):179-83. PubMed ID: 17566884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clock tests in depression, Alzheimer's disease, and elderly controls.
    Herrmann N; Kidron D; Shulman KI; Kaplan E; Binns M; Leach L; Freedman M
    Int J Psychiatry Med; 1998; 28(4):437-47. PubMed ID: 10207742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired insight in Alzheimer disease: association with cognitive deficits, psychiatric symptoms, and behavioral disturbances.
    Harwood DG; Sultzer DL; Wheatley MV
    Neuropsychiatry Neuropsychol Behav Neurol; 2000 Apr; 13(2):83-8. PubMed ID: 10780626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Depressive pseudodementia].
    Fischer P; Bailer U; Hilger E; Leitner I
    Wien Med Wochenschr; 2002; 152(3-4):62-5. PubMed ID: 11925773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury.
    Lee H; Kim SW; Kim JM; Shin IS; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2005 Mar; 20(2):97-104. PubMed ID: 15641125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylphenidate: established and expanding roles in symptom management.
    Prommer E
    Am J Hosp Palliat Care; 2012 Sep; 29(6):483-90. PubMed ID: 22144657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylphenidate as a treatment for depression in acquired immunodeficiency syndrome: an n-of-1 trial.
    White JC; Christensen JF; Singer CM
    J Clin Psychiatry; 1992 May; 53(5):153-6. PubMed ID: 1592840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylphenidate and psychotic depression.
    Ng BK
    Clin Neuropharmacol; 2009; 32(3):177. PubMed ID: 19483495
    [No Abstract]   [Full Text] [Related]  

  • 17. Neurological correlates of depressive symptoms in Alzheimer's disease and vascular dementia.
    Simpson S; Allen H; Tomenson B; Burns A
    J Affect Disord; 1999 May; 53(2):129-36. PubMed ID: 10360407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained-release methylphenidate for cognitive impairment in HIV-1-infected drug abusers: a pilot study.
    van Dyck CH; McMahon TJ; Rosen MI; O'Malley SS; O'Connor PG; Lin CH; Pearsall HR; Woods SW; Kosten TR
    J Neuropsychiatry Clin Neurosci; 1997; 9(1):29-36. PubMed ID: 9017526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A; Richard C; Prinzo R; Binder C
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Incidence and importance of "non-cognitive" symptoms in dementia of the Alzheimer type: productive psychotic symptoms, depressive disorders and behavioral disorders].
    Sattel H; Geiger-Kabisch C; Schreiter-Gasser U; Besthorn C; Förstl H
    Z Gerontol; 1993; 26(4):275-9. PubMed ID: 7692680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.